Last 29 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.77 | — | — | 75.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.16 | 10.96 | 15.63 | 4.86 | 18.42 | 24.14 | 34.37 | 48.31 | 39.23 | 215.43 | 124.50 | — | — | — | — | — | — | — | — | — | — |
| — | -54.6% | -54.5% | -89.9% | -53.0% | -88.8% | -72.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.65 | 8.64 | 7.80 | 5.07 | 10.09 | 3.89 | 1.78 | 1.42 | 1.93 | 1.25 | 2.78 | 1.34 | 0.55 | 0.48 | 0.63 | 0.57 | 0.64 | 0.73 | 1.01 | 1.55 | 2.31 |
| — | +122.3% | +337.9% | +256.7% | +422.2% | +212.0% | -35.9% | +5.9% | +253.8% | +159.8% | +340.6% | +137.0% | -14.7% | -34.5% | -37.7% | -63.5% | -72.2% | -72.6% | -57.9% | -29.4% | -68.3% | |
| P/FCF | — | — | — | 80.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 85.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 31.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.6% | 73.5% | 97.1% | 93.3% | 99.0% | 74.5% | 46.7% | 32.1% | 26.2% | -108.4% | 6.1% | — | — | — | — | — | — | — | — | — | — |
| — | -1.4% | +108.0% | +190.5% | +278.1% | +168.7% | +661.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -338.7% | -93.9% | -161.1% | 4.7% | -81.3% | -430.1% | -1315.7% | -1913.2% | -944.5% | -6616.4% | -32779.4% | — | — | — | — | — | — | — | — | — | — |
| — | +78.2% | +87.8% | +100.2% | +91.4% | +93.5% | +96.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -325.3% | -93.2% | -198.3% | 6.5% | -87.4% | -425.2% | -1220.9% | -1726.2% | -865.8% | -5668.5% | -32229.4% | — | — | — | — | — | — | — | — | — | — |
| — | +78.1% | +83.8% | +100.4% | +89.9% | +92.5% | +96.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.2% | -17.4% | -21.9% | 1.7% | -11.6% | -16.0% | -14.9% | -12.1% | -10.2% | -10.8% | -108.7% | -2.5% | -2.3% | -3.2% | -3.3% | -3.4% | -3.2% | -4.0% | -4.9% | -2.9% | -3.3% |
| — | -8.9% | -47.2% | +114.3% | -13.2% | -47.2% | +86.3% | -388.6% | -351.5% | -241.2% | -3231.8% | +26.4% | +28.1% | +20.5% | +33.7% | -15.7% | +5.0% | -41.7% | -103.0% | +27.5% | +61.7% | |
| ROA | -36.0% | -5.5% | -9.3% | 0.9% | -6.1% | -8.9% | -10.4% | -10.3% | -8.9% | -7.1% | -76.6% | -2.4% | -2.2% | -3.1% | -3.2% | -3.3% | -3.1% | -3.9% | -4.7% | -2.8% | -3.2% |
| — | +38.4% | +10.4% | +108.7% | +31.2% | -26.5% | +86.5% | -330.1% | -303.8% | -128.8% | -2308.7% | +26.7% | +28.2% | +20.2% | +32.9% | -17.3% | +3.9% | -41.9% | -101.7% | +28.0% | +61.4% | |
| ROIC | -54.3% | -8.0% | -17.0% | 1.6% | -11.7% | -18.1% | -16.9% | -10.8% | -8.8% | -10.0% | -88.1% | -2.7% | -2.7% | -3.4% | -3.3% | -3.4% | -3.3% | -3.9% | -4.7% | -3.4% | -4.3% |
| — | +55.7% | -0.6% | +115.2% | -33.2% | -81.2% | +80.9% | -302.4% | -225.7% | -196.1% | -2582.7% | +20.9% | +19.3% | +13.3% | +29.7% | +0.8% | +21.6% | +12.9% | +22.7% | +60.7% | +44.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 2.05 | 0.99 | 0.03 | 0.03 | 0.18 | 0.15 | 0.03 | 0.02 | 0.02 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| — | +1062.8% | +541.2% | +13.0% | +72.7% | +693.2% | +171.3% | +357.6% | +190.3% | +205.0% | +870.0% | -4.0% | +1.8% | +9.0% | -13.1% | +60.9% | +58.8% | — | — | — | — | |
| Debt / EBITDA | — | — | — | 2.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.95 | 7.45 | 8.37 | 7.44 | 6.95 | 8.48 | 9.39 | 9.01 | 9.04 | 9.57 | 11.49 | 38.58 | 44.11 | 38.74 | 47.51 | 51.99 | 50.70 | 48.63 | 33.57 | 34.89 | 45.62 |
| — | -12.1% | -10.8% | -17.5% | -23.1% | -11.4% | -18.3% | -76.6% | -79.5% | -75.3% | -75.8% | -25.8% | -13.0% | -20.3% | +41.5% | +49.0% | +11.2% | -18.8% | -58.3% | -58.1% | +35.4% | |
| Quick Ratio | 6.81 | 7.30 | 8.14 | 7.24 | 6.81 | 8.39 | 9.38 | 9.01 | 9.04 | 9.57 | 11.49 | 38.58 | 44.11 | 38.74 | 47.51 | 51.99 | 50.70 | 48.63 | 33.57 | 34.89 | 45.62 |
| — | -13.0% | -13.2% | -19.7% | -24.6% | -12.3% | -18.3% | -76.6% | -79.5% | -75.3% | -75.8% | -25.8% | -13.0% | -20.3% | +41.5% | +49.0% | +11.2% | -18.8% | -58.3% | -58.1% | +35.4% | |
| Interest Coverage | -13.96 | -5.85 | -8.30 | 1.80 | -4.48 | -8.46 | -139.16 | -984.85 | -554.56 | -342.42 | -3502.73 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NUVB stock.
Nuvation Bio Inc.'s current P/E is -10.8x. The average P/E over the last 1 quarters is 75.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nuvation Bio Inc.'s current operating margin is -338.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nuvation Bio Inc.'s business trajectory between earnings reports.